Phase 1 Macular Degeneration Trial, Recruiting NCT07267026 Sponsor: Consun Pharmaceutical Group Condition: Macular Degeneration
Back to Macular Degeneration

Phase 1 Macular Degeneration Trial, Recruiting

NCT07267026
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman between 18 and 55 years old (inclusive) at the time of screening
  • You weigh at least 50 kg (about 110 lbs) and your Body Mass Index (BMI) falls between 18.5 and 29.9 (a standard measure of body weight relative to height)
  • You are in good general health
  • You are able to understand the study information and are willing to sign a consent form before any study activities begin
  • You agree not to try to conceive a child during the trial and for 3 months after the last dose, are willing to use effective birth control throughout, and do not plan to donate sperm or eggs during this time

Who may not be able to join:

  • You have a significant history of, or currently have, serious heart, lung, digestive, neurological, or blood/immune system conditions
  • You have a long-term digestive condition that requires daily medication, or you have had weight-loss (bariatric) surgery in the past
  • You have received a live or weakened (attenuated) vaccine within 4 weeks before the study dose, or plan to receive one during the study
  • Your blood pressure readings fall outside the acceptable range set by the trial (confirm with trial site)
  • You have a history of heart attack, chest pain (angina), heart surgery or procedures, heart failure, unexplained irregular heartbeat, or a personal or family history of a heart rhythm condition called QT prolongation syndrome
  • You test positive for hepatitis B, hepatitis C, syphilis, or HIV
  • You have had a major surgery or serious injury requiring a hospital stay within the past 6 months
  • You have a known allergy or sensitivity to any ingredient in the study drug (SK-09)
  • You have very difficult veins to access for blood draws, or have a strong fear of needles that would affect your participation
  • You have had problems with alcohol or used recreational drugs within the past 6 months
  • You currently smoke and are unwilling to stop smoking during the study
  • Certain blood test results from your screening appointment are outside the acceptable range, particularly tests related to liver function (confirm with trial site)
  • You have donated or lost more than 400 mL (roughly one pint) of blood in the 3 months before the study dose
  • You have taken part in another clinical trial or received an experimental treatment within 30 days before dosing (or longer, depending on the treatment)
  • You have taken any medications — including over-the-counter medicines, herbal remedies, vitamins, or supplements — within 2 weeks before the first dose (or longer, depending on the product)
  • You are pregnant, have had a positive pregnancy test, or are currently breastfeeding
  • You have had unprotected sex within 2 weeks before the first dose
  • You have any other condition that, in the doctor's opinion, could put you at risk, affect the study results, or prevent you from completing the study
  • You are a staff member directly involved in running this trial, a family member of such staff, or an employee of the company sponsoring the trial who is directly involved in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13936455906

Australian sites

Q-Pharm Pty Ltd., Herston, Queensland
0737072720

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Consun Pharmaceutical Group
Registry
ClinicalTrials.gov
Start date
8 December 2025
Est. completion
4 October 2026

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Safety Evaluation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov